1. Stroke and recurrent haemorrhage associated
with antithrombotic treatment after
gastrointestinal bleeding in patients with atrial
fibrillation
BMJ Published 16 November 2015
7. Study population
デンマークの全住民が登録されているデータベースより同定された、抗血栓薬(vitamin K
antagonist,dabigatran,rivaroxaban,aspirin,clopidogrel,prasugrel,ticagrelor)単剤または併用療法中に
消化管出血を発症した心房細動患者全例。
除外基準:<30歳 or 100歳>、心臓弁膜症、イベント発症前8週以内に股関節・膝関節全置換
術の施行、イベント発症前6カ月以内にDVTまたは肺塞栓症を発症
20. Discussion
2年間で39.9%と累積死亡率は高かった。
消化管出血後に27.1%の患者は抗血栓療法の再開を受けなかった
経口抗凝固薬単剤を再開した群で非再開群と比較しても全死亡率・血栓塞栓症のリスクが最
も低かった(大出血リスクの上昇は認めた)
どの抗血栓療法再開群でも消化管出血再発の重大なリスク上昇には関与しなかった。
The study by Qureshi and colleagues,who reported benefit of restarting warfarin on mortality and thromboembolism
and without the additional cost of recurrent gastrointestinal bleeding
Witt and colleagues found that after gastrointestinal bleeding,restarting warfarin treatment compared with no
treatment was associated with a lower risk of death and thromboembolism without a significantly increased risk of
recurrent gastrointestinal bleeding
Sung and colleagues tested continuation of single treatment with aspirin compared with no treatment after ulcer
related bleeding.The authers concluded that continuing aspirin treatment versus non-resumption potentially
reduced mortality but increased the risk of recurrent gastrointestinal bleeding.